254 related articles for article (PubMed ID: 24875590)
1. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
Quintás-Cardama A; Daver N; Kim H; Dinardo C; Jabbour E; Kadia T; Borthakur G; Pierce S; Shan J; Cardenas-Turanzas M; Cortes J; Ravandi F; Wierda W; Estrov Z; Faderl S; Wei Y; Kantarjian H; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):401-10. PubMed ID: 24875590
[TBL] [Abstract][Full Text] [Related]
2. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
3. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
4. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
5. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
6. The heterogeneity of leukemia occurring after treatment for sarcoma.
Varterasian M; Zalupski M; Karanes C
Am J Clin Oncol; 1997 Dec; 20(6):585-6. PubMed ID: 9391546
[TBL] [Abstract][Full Text] [Related]
7. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Tong WG; Quintás-Cardama A; Kadia T; Borthakur G; Jabbour E; Ravandi F; Faderl S; Wierda W; Pierce S; Shan J; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
Cancer; 2012 Sep; 118(18):4462-70. PubMed ID: 22252728
[TBL] [Abstract][Full Text] [Related]
8. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
9. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
10. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
12. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
[No Abstract] [Full Text] [Related]
13. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
14. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.
Pedersen-Bjergaard J; Andersen MK; Christiansen DH
Blood; 2000 Jun; 95(11):3273-9. PubMed ID: 10828005
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.
Ben-Yehuda D; Krichevsky S; Caspi O; Rund D; Polliack A; Abeliovich D; Zelig O; Yahalom V; Paltiel O; Or R; Peretz T; Ben-Neriah S; Yehuda O; Rachmilewitz EA
Blood; 1996 Dec; 88(11):4296-303. PubMed ID: 8943866
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
Nardi V; Winkfield KM; Ok CY; Niemierko A; Kluk MJ; Attar EC; Garcia-Manero G; Wang SA; Hasserjian RP
J Clin Oncol; 2012 Jul; 30(19):2340-7. PubMed ID: 22585703
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients.
Yokoyama H; Mori S; Kobayashi Y; Kurosawa S; Saito B; Fuji S; Maruyama D; Azuma T; Kim SW; Watanabe T; Tanosaki R; Tobinai K; Takaue Y; Fukuda T
Int J Hematol; 2010 Sep; 92(2):334-41. PubMed ID: 20680530
[TBL] [Abstract][Full Text] [Related]
18. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.
Ye X; Chen D; Zheng Y; Wu C; Zhu X; Huang J
Hematol Oncol; 2019 Oct; 37(4):438-446. PubMed ID: 31378958
[TBL] [Abstract][Full Text] [Related]
19. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
Kröger N; Brand R; van Biezen A; Zander A; Dierlamm J; Niederwieser D; Devergie A; Ruutu T; Cornish J; Ljungman P; Gratwohl A; Cordonnier C; Beelen D; Deconinck E; Symeonidis A; de Witte T;
Haematologica; 2009 Apr; 94(4):542-9. PubMed ID: 19278968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
